BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announced the presentation of new preclinical data on its drug candidate AEF0217 at the 2nd European Conference on Phelan-McDermid Syndrome, which was held from June 9 to 11, 2023 at CEU San Pablo University in Madrid1. Phelan-McDermid Syndrome (PMS), which is caused by the deletion
Source link
